Uridine - Repligen

Drug Profile

Uridine - Repligen

Alternative Names: RG 2417

Latest Information Update: 27 Apr 2011

Price : $50

At a glance

  • Originator McLean Hospital; Repligen
  • Developer Repligen Corporation
  • Class Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Bipolar disorders; Neurodegenerative disorders
  • Discontinued Epilepsy

Most Recent Events

  • 08 Mar 2011 Top-line efficacy and tolerability data from a phase IIb trial in Bipolar disorders released by Repligen
  • 13 Jan 2011 Repligen completes a phase IIb trial for Bipolar disorders in USA
  • 01 Oct 2010 Repligen completes enrolment in a phase IIb trial in Bipolar disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top